Federal prosecutors charged a New Jersey biostatistician with insider trading after allegedly using undisclosed clinical trial results to profit over $450,000. The indictment was unsealed and the defendant arrested, reflecting ongoing enforcement of securities laws in life‑sciences contexts.

U.S. prosecutors in the District of Massachusetts unsealed an indictment charging a New Jersey biostatistician with securities fraud for allegedly trading on material nonpublic information regarding positive clinical trial results from a Massachusetts drugmaker. Authorities say the defendant received advance knowledge of trial outcomes and executed securities transactions that yielded more than $450,000 in illicit profits before the information became public. The indictment alleges a deliberate scheme to exploit nonpublic scientific and clinical data for personal gain, undermining market integrity and investor trust in timely disclosures. The defendant was arrested and presented to a magistrate court; prosecutors indicated the case will proceed with pretrial litigation and potential forfeiture of ill‑gotten gains. This enforcement action aligns with a sustained focus by regulators on insider trading in the biotechnology and pharmaceutical sectors where clinical data can materially affect share prices. Observers note that improved surveillance of trading patterns around trial announcements and closer cooperation between regulators and industry are likely to increase detection of similar schemes.